Replies to post #599819 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Imo, for the most part, definitely. Particularly when combined with adjuvants like poly-iclc, csf1R and Keytruda — amongst others.

(Of course, it is possible that DCDirect version 3.0 and/or hyperactive dendritic cell therapy will reduce the need for any adjuvants)

[ATLnsider]

Yes I do, in fact, I seem to remember Linda Powers saying that was 1 reason they decided to have the Glioblastoma Phase 3 trial first, because if they could prove significant safety and efficacy in treating Glioblastoma, then it should be easier to treat solid tumor cancers in other organs, because you do not have to deal with the blood-brain barrier.

However, because of the immunosuppressive nature of solid tumor cancers micro-environments in general, and regardless of which organ(s) the tumors are located, combination treatments may always need to be used for maximum efficacy.

I hope that anyone else who remembers this statement by Linda Powers, will also chime in.

[Bright Boy]

So I'm going to go out on a limb here in my following comments, but I believe it's time and I believe the scientific/medical community is coming around to believe that Northwest and it's brilliant team from Alton Boynton, Linda Powers, Dr. Bosch, Allen Turner( former NWBO employee), Dr. Linda Liau and her UCLA team, my friend that is truly a legend in the biotech world and everyone else involved in the development/discovery and understanding of the technology that drives the process that is DCVax-L which provides the world of medicine the ability to DIRECT THE IMMUNE SYSTEM and thereby TARGET ALL DISEASES !!!!!!! In simple terms, DCVax-L is able to identify antigens, which in a perfect system, ARE NOT SUPPOSED TO BE THERE !!!! AND GET RID OF THEM!!!!!!!

AND Yes!!! You already know what this means !!! DCVax-L represents the platform technology that is a general application for all diseases !!!!!

Cheers,

BB